Reimagine AI-driven Drug Discovery with Pharma Superintelligence
Explore how AI-driven drug discovery is evolving through Pharmaceutical Superintelligence and what your organisation can do to keep up.
Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
Explore how AI-driven drug discovery is evolving through Pharmaceutical Superintelligence and what your organisation can do to keep up.
Digital health funding hit $7.4B in Q1 2026, the highest since Q2 2022. The CB Insights State of Digital Health report reveals where capital is concentrating and why it matters for pharma leaders.
Pharmacy is emerging as a critical but overlooked route to faster patient access. In this episode of Digital Pulse, Judit Mora explains how innovation, digital workflows, and pharmacy-led models can bypass traditional delays in healthcare delivery.
Phenotypic drug discovery is reshaping how pharma finds first-in-class drugs. This analysis covers the methods, AI integration, and strategic decisions R&D leaders face in 2026.
Cell therapy for solid tumours faces unique biological barriers. This analysis unpacks the engineering strategies pharma leaders must understand for R&D success in 2026.
Precision alone isn’t enough in oncology drug discovery. See why execution, biomarkers, and trial design determine scalable success in precision medicine.
Trisha Pillay speaks with Adriaan Kruger, CEO of nuvoteQ, as they unpack why clinical research is still heavily reliant on paper-based systems in many regions.
Pharmacoinformatics is redefining drug discovery strategy. This analysis covers the AI platforms, molecular design tools, and regulatory frameworks shaping R&D pipelines in 2026.
From 2012 through 2024, the FDA only approved 22 drugs for the treatment of psychiatric conditions. Pharma R&D teams must rethink development strategies to unstall drug innovation in psychiatry
What do pharma R&D tech investment committees really fund? Learn how workflow fit, enterprise pull, and strategic relevance drive adoption.
Explore the biggest drug discovery challenges facing pharma today, from translational gaps to AI integration, and why a new pharma paradigm is needed.
Find out why strategic pharma intelligence is needed to connect insights and to guide confident decision-making across the drug development lifecycle.